Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
Astellas Pharma

Astellas Pharma

Pharmaceutical company

Appears in 1 story

Stories

First CLDN18.2 antibody-drug conjugate reaches regulatory review for gastric cancer

New Capabilities

Maker of the first approved CLDN18.2 drug

Advanced gastric cancer that returns after treatment usually kills within about six months. On June 4, 2026, Chinese biotech Innovent Biologics said its drug had slowed that clock in a late-stage trial.

Updated 2 hours ago